Literature DB >> 8513823

Severe neutropenia in a patient treated with imipenem/cilastatin.

M C Fariñas, T de Vega, J Garmendia, J González-Macías.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513823     DOI: 10.1007/BF01967266

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Neutropenia complicating parenteral antibiotic treatment of infected nonunion of the tibia.

Authors:  W P McCluskey; J L Esterhai; C T Brighton; R B Heppenstall
Journal:  Arch Surg       Date:  1989-11

2.  Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin.

Authors:  G B Calandra; K R Brown; L C Grad; V I Ahonkhai; C Wang; M A Aziz
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

3.  Neutropenia due to beta lactamine antibodies.

Authors:  B Rouveix; K Lassoued; D Vittecoq; B Regnier
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-17

4.  A prospective study of neutropenia induced by high doses of beta-lactam antibiotics.

Authors:  L Olaison; K Alestig
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

5.  Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.

Authors:  G Calandra; E Lydick; J Carrigan; L Weiss; H Guess
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

  5 in total
  3 in total

Review 1.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Meropenem-Induced Neutropenia in a Neonate.

Authors:  Joseph S Van Tuyl; Aubrey N Jones; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug

Review 3.  Adverse effects of monobactams and carbapenems.

Authors:  G Alván; C E Nord
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.